您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Conoidin A
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Conoidin A
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Conoidin A图片
CAS NO:18080-67-6
包装与价格:
包装价格(元)
10 mM * 1 mL in DMSO电议
25mg电议
100mg电议
200mg电议
500mg电议

产品介绍
Conoidin A 是刚地弓形虫过氧化物酶 II (TgPrxII) 的细胞通透性抑制剂,有杀线虫的特性。Conoidin A 共价结合 TgPrxII 的过氧化物催化位点 Cys47,不可逆地抑制其过氧化物活性,IC50为 23 μM。Conoidin A 也抑制哺乳动物 PrxI 和 PrxII (但不抑制 PrxIII) 的氧化。Conoidin A 具有抗氧化、神经保护作用,并且可用于缺血性心脏病的研究。
生物活性

Conoidin A is a cell permeable inhibitor of T. gondiienzyme peroxiredoxin II (TgPrxII)with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with anIC50of 23 μM. Conoidin A also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII)[1][2]. Conoidin A has antioxidant, neuroprotective effects and can be used for the research of ischaemic heart disease[3].

IC50& Target

Toxoplasma

 

体外研究
(In Vitro)

Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer[1].
Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity in vitro. Conoidin A also shown to alkylate or crosslink catalytic cysteines of wild type AcePrx-1 in Ancylostoma ceylanicum and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII[2].
Conoidin A (5 μM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II[2].

体内研究
(In Vivo)

Conoidin A (intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST‐segment elevation. Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐ reatment with conoidin A abolishs the effect of Luteolin. Pre‐ reatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDHin vivo[3].

Animal Model:Rat myocardial I/R model[3]
Dosage:5 mg/kg
Administration:Intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury
Result:Significantly reversed the antioxidative effect of Luteolin.
Impaired the protective effects of luteolin.
分子量

347.99

性状

Solid

Formula

C10H8Br2N2O2

CAS 号

18080-67-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 14.29 mg/mL(41.06 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.8736 mL14.3682 mL28.7365 mL
5 mM0.5747 mL2.8736 mL5.7473 mL
10 mM0.2874 mL1.4368 mL2.8736 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 1.43 mg/mL (4.11 mM); Clear solution

    此方案可获得 ≥ 1.43 mg/mL (4.11 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 14.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
*以上所有助溶剂都可在本网站选购。